Finance

Beta
Lists
032300:KOSDAQ
Korea Pharma Co Ltd
₩9,440.00
-2.28%
(-220.00) 1D
May 29, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 032300...
Open
₩9,670
High
₩9,860
Low
₩9,400
Mkt. cap
102.96B
Avg. vol.
25.53K
Volume
30.30K
Dividend
0.53%
Quarterly dividend
₩12
Ex-dividend date
Dec 27, 2024
52-wk high
₩18,710
52-wk low
₩9,400
EPS
-₩227
Shares outstanding
10.91M
No. of employees
283
Open
₩9,670
High
₩9,860
Low
₩9,400
Mkt. cap
102.96B
Avg. vol.
25.53K
Volume
30.30K
Dividend
0.53%
Quarterly dividend
₩12
Ex-dividend date
Dec 27, 2024
52-wk high
₩18,710
52-wk low
₩9,400
EPS
-₩227
Shares outstanding
10.91M
No. of employees
283
News stories
From sources across the web
About Korea Pharma Co Ltd
CEOPark Eun-hee
Employees283
Founded1974
Headquarters-
SectorPharmaceutical industry
Websitekoreapharma.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
23.39B
24.00B
19.43B
24.60B
Cost of goods sold
15.25B
15.28B
13.79B
15.52B
Cost of revenue
15.25B
15.28B
13.79B
15.52B
Research and development expenses
986.35M
497.60M
519.81M
538.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.44B
7.00B
6.82B
6.61B
Operating expense
8.06B
8.21B
7.95B
7.78B
Total operating expenses
23.30B
23.49B
21.74B
23.30B
Operating income
82.57M
507.40M
-2.31B
1.31B
Other non operating income
1.70M
-2.64M
-1.02B
40.48M
EBT including unusual items
-697.57M
-155.65M
-4.18B
763.09M
EBT excluding unusual items
-855.72M
-238.06M
-4.17B
508.49M
Income tax expense
-321.80M
-134.74M
-1.42B
80.61M
Effective tax rate
46.13%
86.57%
33.95%
10.56%
Other operating expenses
128.74M
157.70M
131.92M
149.25M
Net income
-375.78M
-20.90M
-2.76B
682.48M
Net profit margin
-1.61%
-0.09%
-14.19%
2.77%
Earnings per share
-
-
-
-
Interest and investment income
121.82M
183.53M
228.72M
243.76M
Interest expense
-911.28M
-925.10M
-952.60M
-988.26M
Net interest expenses
-789.46M
-741.57M
-723.88M
-744.50M
Depreciation and amortization charges
312.46M
310.55M
311.79M
309.28M
EBITDA
881.64M
1.29B
-1.53B
2.07B
Gain or loss from assets sale
-
-
-1.22M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer